{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:34:28Z","timestamp":1783661668437,"version":"3.55.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.neuropharm.2025.110386","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:04:00Z","timestamp":1740701040000},"page":"110386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["\u03b2-2 agonist and antagonist adrenoceptors induce neuroprotection in a progressive model of parkinsonism"],"prefix":"10.1016","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8383-8495","authenticated-orcid":false,"given":"Auderlan M.","family":"de Gois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.M.","family":"Bispo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edson R.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina F.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3665-5810","authenticated-orcid":false,"given":"Jo\u00e3o E.C.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5351-4086","authenticated-orcid":false,"given":"Mylaine S.","family":"Mendon\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8977-9337","authenticated-orcid":false,"given":"Thiago H.","family":"Almeida-Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enilton A.","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katty A.A.L.","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pollyana C.","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heitor F.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00edvia C.R.F.","family":"Lins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7697-5766","authenticated-orcid":false,"given":"Alessandra M.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9017-3922","authenticated-orcid":false,"given":"Regina H.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110386_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neuropharm.2004.04.003","article-title":"Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia","volume":"47","author":"Ab\u00edlio","year":"2004","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110386_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF03256657","article-title":"Adverse effects of \u03b2-agonists are they clinically relevant?","volume":"2","author":"Abramson","year":"2003","journal-title":"Am. J. Respir. Med."},{"key":"10.1016\/j.neuropharm.2025.110386_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.parkreldis.2018.02.046","article-title":"Neurite orientation dispersion and density imaging of the nigrostriatal pathway in Parkinson's disease: retrograde degeneration observed by tract-profile analysis","volume":"51","author":"Andica","year":"2018","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.neuropharm.2025.110386_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejphar.2013.04.035","article-title":"Synergistic, but not separate, stimulation of accumbal \u03b21- and \u03b22-adrenoceptors alters the accumbal dopamine efflux in freely moving rats","volume":"715","author":"Aono","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2025.110386_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jchemneu.2013.03.001","article-title":"Projections from the rat cuneiform nucleus to the A7, A6 (locus coeruleus), and A5 pontine noradrenergic cell groups","volume":"50\u201351","author":"Bajic","year":"2013","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2025.110386_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049088","article-title":"Beta-adrenergic modulation of tremor and corticomuscular coherence in humans","volume":"7","author":"Baker","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110386_bib8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.pbb.2011.09.009","article-title":"Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by \u03b1- and \u03b2-adrenergic receptor antagonists in hemiparkinsonian rats","volume":"100","author":"Barnum","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2025.110386_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001726.pub5","article-title":"Beta2\u2010agonists for acute cough or a clinical diagnosis of acute bronchitis","author":"Becker","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2025.110386_bib10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/jnc.13125","article-title":"Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat","volume":"2","author":"Bhide","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110386_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbr.2019.01.041","article-title":"Sex differences in the progressive model of parkinsonism induced by reserpine in rats","volume":"363","author":"Bispo","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110386_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2025.110386_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/archneurol.2009.287","article-title":"Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease","volume":"67","author":"Brodsky","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib14","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cne.23024","article-title":"Spinal projections of the A5, A6 (locus coeruleus), and A7 noradrenergic cell groups in rats","volume":"520","author":"Bruinstroop","year":"2012","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2024.114873","article-title":"Behavioral effects of 6-hydroxydopamine-induced damage to nigro-striatal pathway and Locus coeruleus as a rodent model of Parkinson's disease","volume":"462","author":"Bustelli","year":"2024","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110386_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1113\/jphysiol.1983.sp014927","article-title":"Beta\u2010adrenoceptor adaptation to acute exercise","volume":"344","author":"Butler","year":"1983","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.nicl.2017.03.011","article-title":"Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease","volume":"14","author":"Caminiti","year":"2017","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.neuropharm.2025.110386_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1476-5381.1982.tb09216.x","article-title":"\u03b2\u2010ADRENOCEPTOR agonists enhance 5\u2010HYDROXYTRYPTAMINE\u2010MEDIATED behavioural responses","volume":"76","author":"Cowen","year":"1982","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00213-015-4118-4","article-title":"Behavioral and neurochemical effects induced by reserpine in mice","volume":"233","author":"De Freitas","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110386_bib20","doi-asserted-by":"crossref","first-page":"103410","DOI":"10.1016\/j.mcn.2019.103410","article-title":"L-type Ca(2+) channels and charybdotoxin-sensitive Ca(2+)-activated K(+) channels are required for reduction of GABAergic activity induced by \u03b22-adrenoceptor in the prefrontal cortex","volume":"101","author":"Deng","year":"2019","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110386_bib21","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1017\/S1461145713000631","article-title":"Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice","volume":"16","author":"Dobarro","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2020.111198","article-title":"Balance alterations and reduction of pedunculopontine cholinergic neurons in early stages of parkinsonism in middle-aged rats","volume":"145","author":"dos Santos","year":"2021","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0278-5846(00)00169-X","article-title":"Some behavioural effects of ANTIDEPRFSSANT drugs are time-dependent","volume":"25","author":"Dziedzicka-wasylewska","year":"2001","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110386_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mdc3.12408","article-title":"Resting and reemergent tongue tremor as presenting symptoms of Parkinson's disease","volume":"4","author":"Fabbri","year":"2016","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.neuropharm.2025.110386_bib25","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson's disease: substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2025.110386_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-023-03122-z","article-title":"Nonselective beta-adrenoceptor blocker use and risk of Parkinson's disease: from multiple real-world evidence","volume":"21","author":"Feng","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.neuropharm.2025.110386_bib27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbr.2012.03.008","article-title":"Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's disease","volume":"231","author":"Fernandes","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110386_bib28","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/mds.27700","article-title":"MDS evidence-based review of treatments for essential tremor","volume":"34","author":"Ferreira","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2025.110386_bib29","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00210-001-0488-8","article-title":"Inhibition by viozan of extravasation induced in rat trachea by capsaicin is mediated exclusively by \u03b22-adrenoceptors","volume":"364","author":"Fozard","year":"2001","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.neuropharm.2025.110386_bib30","doi-asserted-by":"crossref","first-page":"8526","DOI":"10.1073\/pnas.1605063113","article-title":"Astrocytic \u03b22-adrenergic receptors mediate hippocampal long-term memory consolidation","volume":"113","author":"Gao","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110386_bib31","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/BF01291788","article-title":"Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man","volume":"103","author":"Gerlach","year":"1996","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2025.110386_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/aje\/kwaa012","article-title":"\u03b22-Agonists and the incidence of Parkinson disease","volume":"189","author":"Giorgianni","year":"2020","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0091-3057(84)90210-7","article-title":"Stimulation of beta-adrenergic receptors and spontaneous motor activity in mice","volume":"21","author":"Goldschmidt","year":"1984","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2025.110386_bib34","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/archneur.63.4.584","article-title":"Motor score of the unified Parkinson disease rating scale as a good predictor of lewy body-associated neuronal loss in the substantia nigra","volume":"63","author":"Greffard","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib35","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/mds.108","article-title":"\u03b22-adrenoceptor agonists and antagonists and risk of Parkinson's disease","volume":"33","author":"Gronich","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2025.110386_bib36","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/cercor\/bht429","article-title":"Locus coeruleus stimulation facilitates long-term depression in the dentate gyrus that requires activation of \u03b2-adrenergic receptors","volume":"25","author":"Hansen","year":"2015","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2025.110386_bib37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40478-018-0541-1","article-title":"A53T-\u03b1-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia","volume":"6","author":"Henrich","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neuropharm.2025.110386_bib38","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/SLA.0b013e318265427e","article-title":"Long-term propranolol use in severely burned pediatric patients: a randomized controlled study","volume":"256","author":"Herndon","year":"2012","journal-title":"Ann. Surg."},{"key":"10.1016\/j.neuropharm.2025.110386_bib39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.neuint.2010.03.019","article-title":"Adrenoceptors in brain: cellular gene expression and effects on astrocytic metabolism and [Ca(2+)]i","volume":"57","author":"Hertz","year":"2010","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2025.110386_bib40","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000445751","article-title":"The incidence of Parkinson's disease: a systematic review and meta-analysis","volume":"46","author":"Hirsch","year":"2016","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.neuropharm.2025.110386_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(19)30400-4","article-title":"\u03b2-adrenoreceptors and the risk of Parkinson's disease","author":"Hopfner","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib42","doi-asserted-by":"crossref","first-page":"E135","DOI":"10.1212\/WNL.0000000000007694","article-title":"Use of \u03b22-Adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease","volume":"93","author":"Hopfner","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2025.110386_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1073\/pnas.1309143110","article-title":"Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model","volume":"110","author":"Janezic","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110386_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cercor\/bhm177","article-title":"Pre- and postsynaptic \u03b2-adrenergic activation enhances excitatory synaptic transmission in layer V\/VI pyramidal neurons of the medial prefrontal cortex of rats","volume":"18","author":"Ji","year":"2008","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2025.110386_bib45","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/glia.22801","article-title":"A novel role of microglial NADPH oxidase in mediating extra-synaptic function of norepinephrine in regulating brain immune homeostasis","volume":"63","author":"Jiang","year":"2015","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2025.110386_bib46","doi-asserted-by":"crossref","first-page":"710","DOI":"10.4103\/0028-3886.383852","article-title":"A role of \u03b22-adrenoreceptor agonists related to the development of Parkinson's disease","volume":"71","author":"Jung","year":"2023","journal-title":"Neurol. India"},{"key":"10.1016\/j.neuropharm.2025.110386_bib47","first-page":"1","article-title":"\u03b1-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease","volume":"16","author":"Kang","year":"2018","journal-title":"EMBO J."},{"key":"10.1016\/j.neuropharm.2025.110386_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111207","article-title":"Formoterol attenuated mitochondrial dysfunction in rotenone-induced Parkinson's disease in a rat model: role of PINK-1\/PARKIN and PI3K\/Akt\/CREB\/BDNF\/TrKB axis","volume":"125","author":"Khidr","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.expneurol.2013.11.009","article-title":"Alpha-synuclein interferes with cAMP\/PKA-dependent upregulation of dopamine \u03b2-hydroxylase and is associated with abnormal adaptive responses to immobilization stress","volume":"252","author":"Kim","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib50","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12272-011-0518-0","article-title":"Interference of alpha-synuclein with cAMP\/PKA-dependent CREB signaling for tyrosine hydroxylase gene expression in SK-N-BE(2)C cells","volume":"34","author":"Kim","year":"2011","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.neuropharm.2025.110386_bib51","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/mds.20604","article-title":"Alpha-synuclein immunohistochemistry in two cases of co-occurring idiopathic Parkinson's disease and motor neuron disease","volume":"20","author":"Klos","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2025.110386_bib52","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1038\/s41598-019-41756-3","article-title":"Stimulation of noradrenergic transmission by reboxetine is beneficial for a mouse model of progressive parkinsonism","volume":"9","author":"Kreiner","year":"2019","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110386_bib53","first-page":"432","article-title":"Re-emergent tremor of Parkinson\u2019s disease","volume":"31","author":"Kumar","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.neuropharm.2025.110386_bib54","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchemneu.2018.12.011","article-title":"Serotonergic dysfunction in a model of parkinsonism induced by reserpine","volume":"96","author":"Leal","year":"2019","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2025.110386_bib55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.brainresbull.2019.01.009","article-title":"Cognitive and anxiety-like impairments accompanied by serotonergic ultrastructural and immunohistochemical alterations in early stages of parkinsonism","volume":"146","author":"Leal","year":"2019","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2025.110386_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2017.00078","article-title":"Spontaneously hypertensive rats (SHR) are resistant to a reserpine-induced progressive model of Parkinson's disease: differences in motor behavior, tyrosine hydroxylase and \u03b1-synuclein expression","volume":"9","author":"Le\u00e3o","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110386_bib57","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/bpa.12253","article-title":"Molecular, neurochemical, and behavioral hallmarks of reserpine as a model for Parkinson's disease: new perspectives to a long-standing model","volume":"25","author":"Le\u00e3o","year":"2015","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib58","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuro.2022.10.016","article-title":"Propranolol hydrochloride induces neurodevelopmental toxicity and locomotor disorders in zebrafish larvae","volume":"93","author":"Li","year":"2022","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuropharm.2025.110386_bib59","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fncel.2018.00241","article-title":"Investigation of behavioral dysfunctions induced by monoamine depletions in a mouse model of Parkinson's disease","volume":"12","author":"Li","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110386_bib60","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1124\/jpet.111.179416","article-title":"Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat","volume":"337","author":"Lindenbach","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110386_bib61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.brainresbull.2018.01.017","article-title":"Carvacrol prevents impairments in motor and neurochemical parameters in a model of progressive parkinsonism induced by reserpine","volume":"139","author":"Lins","year":"2018","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2025.110386_bib62","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1126\/science.aaw8981","article-title":"Mechanism of \u03b22AR regulation by an intracellular positive allosteric modulator","volume":"364","author":"Liu","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2025.110386_bib63","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/s41593-019-0511-3","article-title":"Neuronal network activity controls microglial process surveillance in awake mice via norepinephrine signaling","volume":"22","author":"Liu","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110386_bib64","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/jnc.14248","article-title":"Clenbuterol reduces GABAergic transmission in prefrontal cortex layer 5\/6 pyramidal neurons of juvenile rat via reducing action potentials firing frequency of GABAergic interneurons","volume":"144","author":"Luo","year":"2018","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110386_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200216010-00001","article-title":"Potential of \u03b22-adrenoceptor agonists as add-on therapy for multiple sclerosis focus on salbutamol (albuterol)","volume":"16","author":"Makhlouf","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2025.110386_bib66","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.neuroscience.2018.01.053","article-title":"Dopamine, noradrenaline and serotonin receptor densities in the striatum of hemiparkinsonian rats following botulinum neurotoxin-A injection","volume":"374","author":"Mann","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2025.110386_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-019-0074-8","article-title":"State-level prevalence, health service use, and spending vary widely among Medicare beneficiaries with Parkinson disease","volume":"5","author":"Mantri","year":"2019","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.neuropharm.2025.110386_bib68","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/(SICI)1098-2396(20000601)36:3<178::AID-SYN3>3.0.CO;2-6","article-title":"\u03b2-Adrenergic receptors primarily are located on the dendrites of granule cells and interneurons but also are found on astrocytes and a few presynaptic profiles in the rat dentate gyrus","volume":"36","author":"Milner","year":"2000","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2025.110386_bib69","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"Beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson's disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2025.110386_bib70","first-page":"1","article-title":"\u03b22-adrenergic receptor haplotype may be associated with susceptibility to desensitization to long-acting \u03b22-agonists in COPD patients","author":"Mochizuki","year":"2012","journal-title":"Lung"},{"key":"10.1016\/j.neuropharm.2025.110386_bib71","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/jnnp-2015-312283","article-title":"Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis","volume":"87","author":"Moisan","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110386_bib72","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.neuint.2013.07.002","article-title":"Protective effect of nebivolol on reserpine-induced neurobehavioral and biochemical alterations in rats","volume":"63","author":"Nade","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2025.110386_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276368","article-title":"Association between use of \u00df2-adrenergic receptor agonists and incidence of Parkinson's disease: retrospective cohort analysis","volume":"17","author":"Nadeem","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110386_bib74","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.rmed.2004.02.024","article-title":"Tremor side effects of salbutamol, quantified by a laser pointer technique","volume":"98","author":"Nizet","year":"2004","journal-title":"Respir. Med."},{"key":"10.1016\/j.neuropharm.2025.110386_bib75","article-title":"Resting and re-emergent tongue tremor in Parkinson's disease","volume":"1","author":"Numao","year":"2017","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.neuropharm.2025.110386_bib76","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF02245705","article-title":"Differential sensitivity to the effects of albuterol on locomotor activity and operant behavior","volume":"113","author":"O'Donnell","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110386_bib77","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.4103\/1673-5374.235219","article-title":"Targeting the noradrenergic system for anti-inflammatory and neuroprotective effects: implications for Parkinson's disease","volume":"13","author":"O'Neill","year":"2018","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.neuropharm.2025.110386_bib78","article-title":"Pharmacological targeting of \u03b2 2 \u2010adrenoceptors is neuroprotective in the LPS inflammatory rat model of Parkinson's disease","volume":"6701","author":"O'Neill","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib79","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/hr.2014.112","article-title":"Expression and functions of \u03b21- and \u03b22-adrenergic receptors on the bulbospinal neurons in the rostral ventrolateral medulla","volume":"37","author":"Oshima","year":"2014","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.neuropharm.2025.110386_bib80","first-page":"192","article-title":"Comparative study on effects of nebulized and oral salbutamol on a cecal ligation and puncture-induced sepsis model in rats","volume":"65","author":"Ozogul","year":"2015","journal-title":"Drug Res."},{"key":"10.1016\/j.neuropharm.2025.110386_bib81","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2147\/CLEP.S405325","article-title":"\u03b22-Adrenoceptor agonists in asthma or chronic obstructive pulmonary disease and risk of Parkinson's disease: nested case-control study","volume":"15","author":"Paakinaho","year":"2023","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib82","first-page":"2159","article-title":"Protective effect of Rubia cordifolia on reserpine-induced orofacial dyskinesia","volume":"26","author":"Patil","year":"2011","journal-title":"Nat. Prod. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110386_bib83","first-page":"1","article-title":"Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein","volume":"8","author":"Patterson","year":"2022","journal-title":"npj Parkinson\u2019s Disease"},{"key":"10.1016\/j.neuropharm.2025.110386_bib84","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2007"},{"key":"10.1016\/j.neuropharm.2025.110386_bib85","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fphar.2016.00343","article-title":"Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats","volume":"7","author":"Peres","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib86","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-015-0044-5","article-title":"Pharmacogenetic stimulation of cholinergic pedunculopontine neurons reverses motor deficits in a rat model of Parkinson's disease","volume":"10","author":"Pienaar","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2025.110386_bib87","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.nbd.2010.05.028","article-title":"Staging of serotonergic dysfunction in Parkinson's Disease: an in vivo 11C-DASB PET study","volume":"40","author":"Politis","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110386_bib88","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/glia.20873","article-title":"\u03b22 adrenergic receptor activation induces microglial NADPH oxidase activation and dopaminergic neurotoxicity through an ERK-dependent\/protein kinase A-independent pathway","volume":"57","author":"Qian","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2025.110386_bib89","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.4049\/jimmunol.1002449","article-title":"\u03b22-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway","volume":"186","author":"Qian","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib90","first-page":"696","article-title":"Decreased sleep quality in Parkinson's patients is associated with higher anxiety and depression prevalence and severity, and correlates with pain intensity and quality","volume":"40","author":"Rana","year":"2018","journal-title":"Neurol. Res."},{"key":"10.1016\/j.neuropharm.2025.110386_bib91","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Ray Dorsey","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib92","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.neuint.2013.07.006","article-title":"Stimulation of central \u03b22-adrenoceptors suppresses NF\u03baB activity in rat brain: a role for I\u03baB","volume":"63","author":"Ryan","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2025.110386_bib93","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1016\/j.celrep.2018.05.059","article-title":"Aberrant striatal activity in parkinsonism and levodopa-induced dyskinesia","volume":"23","author":"Ryan","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2025.110386_bib94","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbr.2013.06.031","article-title":"Cognitive, motor and tyrosine hydroxylase temporal impairment in a model of parkinsonism induced by reserpine","volume":"253","author":"Santos","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110386_bib95","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.resuscitation.2006.07.001","article-title":"\u03b2-Adrenergic blockade during systemic inflammation: impact on cellular immune functions and survival in a murine model of sepsis","volume":"72","author":"Schmitz","year":"2007","journal-title":"Resuscitation"},{"key":"10.1016\/j.neuropharm.2025.110386_bib96","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ana.25341","article-title":"\u03b22-adrenoreceptor medications and risk of Parkinson disease","volume":"84","author":"Searles Nielsen","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.crneur.2023.100105","article-title":"Propranolol reduces the accumulation of cytotoxic aggregates in C9orf72-ALS\/FTD in vitro models","volume":"5","author":"Seidel","year":"2023","journal-title":"Current Research in Neurobiology"},{"key":"10.1016\/j.neuropharm.2025.110386_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101670","article-title":"Beta-adrenergic drugs and risk of Parkinson's disease: a systematic review and meta-analysis","volume":"80","author":"Singh","year":"2022","journal-title":"Ageing Res. Rev."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110386_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-46511-3","article-title":"Polysorbate 80 surface modified SLNs of formoterol suppress SNCA gene and mitochondrial oxidative stress in mice model of Parkinson's disease","volume":"13","author":"Sola","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110386_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-022-04121-1","article-title":"Inhibition of VMAT2 by \u03b22-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone","volume":"5","author":"St\u00f8ve","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib101","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41593-019-0514-0","article-title":"Noradrenergic signaling in the wakeful state inhibits microglial surveillance and synaptic plasticity in the mouse visual cortex","volume":"22","author":"Stowell","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110386_bib102","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12974-019-1632-z","article-title":"Stress-induced microglial activation occurs through \u03b2-adrenergic receptor: noradrenaline as a key neurotransmitter in microglial activation","volume":"16","author":"Sugama","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2025.110386_bib103","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2131\/jts.30.305","article-title":"TISSUE- and dose-dependent alteration of stress-inducible proteins by \u03b22-ADRENOCEPTOR agonist, salbutamol, in rats","volume":"30","author":"Tanaka","year":"2005","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110386_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-023-02748-3","article-title":"Opposing effects of \u03b2-2 and \u03b2-1 adrenergic receptor signaling on neuroinflammation and dopaminergic neuron survival in \u03b1-synuclein-mediated neurotoxicity","volume":"20","author":"Torrente","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2025.110386_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/438912","article-title":"Anti-inflammatory and antinociceptive effects of salbutamol on acute and chronic models of inflammation in rats: involvement of an antioxidant mechanism","volume":"2012","author":"Uzkeser","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.neuropharm.2025.110386_bib106","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s11055-017-0522-z","article-title":"Localization of \u03b1 -synuclein in the rat brain and its relationship with dopaminergic structures","volume":"47","author":"Voronkov","year":"2017","journal-title":"Neurosci. Behav. Physiol."},{"key":"10.1016\/j.neuropharm.2025.110386_bib107","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.nicl.2018.03.001","article-title":"Serotonergic dysregulation is linked to sleep problems in Parkinson's disease","volume":"18","author":"Wilson","year":"2018","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.neuropharm.2025.110386_bib108","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.neulet.2017.08.016","article-title":"Selective cholinergic depletion of pedunculopontine tegmental nucleus aggravates freezing of gait in parkinsonian rats","volume":"659","author":"Xiao","year":"2017","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110386_bib109","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bbi.2018.01.004","article-title":"Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the \u03b12-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson's disease","volume":"69","author":"Yssel","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2025.110386_bib110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0091-3057(99)00198-7","article-title":"Effects of adrenoceptor agents on apomorphine-induced licking behavior in rats","volume":"65","author":"Zarrindast","year":"2000","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2025.110386_bib111","doi-asserted-by":"crossref","first-page":"13572","DOI":"10.4238\/2015.October.28.17","article-title":"Effects of beta 2 adrenergic agonists on axonal injury and mitochondrial metabolism in experimental autoimmune encephalomyelitis rats","volume":"14","author":"Zhang","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.neuropharm.2025.110386_bib112","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1101\/lm.030411.113","article-title":"Activation of \u03b22-adrenoceptor enhances synaptic potentiation and behavioral memory via cAMP-PKA signaling in the medial prefrontal cortex of rats","volume":"20","author":"Zhou","year":"2013","journal-title":"Learn. Mem."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825000929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825000929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T16:31:03Z","timestamp":1742747463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825000929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":112,"alternative-id":["S0028390825000929"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110386","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b2-2 agonist and antagonist adrenoceptors induce neuroprotection in a progressive model of parkinsonism","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110386"}}